



Supplementary Figure 4. T1-weighted Gd-enhancement in SELs (all SEL candidates).

Legend

Box plot representation where y-axis scale is based on arcsine transformation. Red asterisks represent the mean values. Consistent results were observed in both RMS and PPMS study populations, separately.

^aVolume normalized average: $\text{sum}(\text{proportion of baseline T2 lesion voxels that is Gd-enhancing for each lesion} \times \text{T2 volume}) / \text{sum of T2 volume}$. T2 volume for SEL, new T2 lesion at Week 24 and at Week 48 are T2 volume at baseline, Week 24, and Week 48, respectively. SELs identified using scans from all scheduled visits. ^bVan Elteren test; stratified by treatment group (ocrelizumab, control), baseline T2 lesion volume category based on tertiles ($\leq 3.013 \text{ cm}^3$, $< 3.013 \text{ cm}^3 - \leq 11.122 \text{ cm}^3$, $> 11.122 \text{ cm}^3$).

Gd: gadolinium; PPMS: primary progressive multiple sclerosis; RMS: relapsing multiple sclerosis; SEL: slowly expanding/evolving lesion.